BBIO BridgeBio Pharma Inc

Corient Private Wealth LLC purchased a new stake of 14,894 shares, valued at approximately $643,000, in BridgeBio Pharma, Inc. during the second quarter. Other institutional investors also adjusted their positions, resulting in institutional ownership of 99.85% for BridgeBio Pharma. Despite recent heavy insider selling, Wall Street sentiment remains largely positive with 21 analysts rating BBIO a "Buy" and an average target price of $77.63.

BridgeBio Pharma, Inc. announced equity grants to 9 new employees consisting of restricted stock units for an aggregate of 29,472 shares of common stock. These grants were approved by the compensation committee on December 18, 2025, as inducements for employment in accordance with Nasdaq Listing Rule 5635(c)(4). The grants vest over a period, starting November 16, 2026, contingent upon continued employment.

BridgeBio Pharma Inc. (BBIO) stock reached an all-time high of $77.32, marking a significant milestone after a 188.03% increase over the past year. The company's shares climbed steadily due to promising clinical trial results and strategic partnerships, despite analysts not expecting profitability this fiscal year. BridgeBio also reported a larger-than-expected Q3 2025 loss but surpassed revenue forecasts, driven by strong sales of their drug Attruby.

BridgeBio Pharma's stock has reached an all-time high of $77.32, driven by strong investor confidence and promising clinical trial results. The company has seen a remarkable 188.03% increase over the past year and an 82.84% return in the last six months. Analysts anticipate future sales growth, and recent Q3 2025 earnings show strong revenue performance and upward revised price targets from several firms.

BridgeBio Pharma, Inc. announced equity grants to nine new employees on December 18, 2025, comprising 29,472 shares of common stock in restricted stock units. These grants, vesting over time and tied to continued employment, were made as an inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4). The grants fall under a plan adopted in 2019 and amended in 2023 by BridgeBio's board of directors.

BridgeBio Pharma Inc. stock has reached an all-time high of $77.32, marking a significant milestone driven by a 188.03% increase over the past year and strong investor confidence. The biotechnology firm, known for innovative genetic disease therapies, has reported surpassing revenue expectations for Q3 2025, with analysts subsequently raising price targets.